Clearmind Medicine Inc. (CMND) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1220 West 6th Avenue
Vancouver, BC V6H 1A5
Canada
Phone
604 260 1566
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
November 15, 2022
| Name | Title | Pay | Year Born |
| Adi Zuloff-Shani | Chief Executive Officer | 304,773 | 1967 |
| Alan Mark Rootenberg | Chief Financial Officer | 0 | 1952 |
| Adi Varon | Controller | 0 | N/A |
| Mary-Elizabeth Gifford | Chief of Global Impact | 0 | N/A |
| Mylene Touboul | Accounting Manager | 0 | N/A |
| Mark Haden | Vice President of Business Development | 0 | 1953 |
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.